Drugmaker GSK (GlaxoSmithKline) has said it is “well positioned” to cope with any financial impact from changes to US tariff ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according ...

Arizona sued drug manufacturer GlaxoSmithKline over what it calls deceptive practices involving the inhaled corticosteroid Flovent that endangered asthma patients. The lawsuit filed Thursday in ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The company’s shares closed yesterday ...

At GlaxoSmithKline, we never lose sight of the fact that patients are at the core of what we do and that millions of lives are impacted by cancer. The patient’s voice is at the heart of our ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

Jeanne Whalen writes about the U.S. economy from the Chicago bureau. She previously covered healthcare, general news and ...

In a report released today, Benjamin Jackson CFA from Jefferies maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. Protect Your ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

In a report released today, Jo Walton from UBS maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of ...